FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS
AGENCE NATIONALE DU MEDICAMENT VETERINAIRE
8 rue Claude Bourgelat –
Parc d’activités de la grande Marche –
Javené – CS 70611 –
35306 FOUGERES

DECENTRALISED PROCEDURE
PUBLICLY AVAILABLE ASSESSMENT REPORT
FOR A VETERINARY MEDICINAL PRODUCT
ARIXIL VET 5 film-coated tablet for dogs and cats
DATE : OCTOBER 2018
# PRODUCT SUMMARY

<table>
<thead>
<tr>
<th>EU Procedure number</th>
<th>FR/V/0330/001/DC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name, strength and pharmaceutical form</td>
<td>ARIXIL VET 5 film-coated tablet for dogs and cats</td>
</tr>
</tbody>
</table>
| Applicant | VETPHARMA ANIMAL HEALTH  
Les Corts, 23  
08028 Barcelona  
SPAIN |
| Active substance(s) | Benazepril (as benazepril hydrochloride) |
| ATC Vetcode | QC09AA07 |
| Target species | Dogs and cats |
| Indication for use | DOGS: Treatment of congestive heart failure.  
CATS: Reduction of proteinuria associated with chronic kidney disease. |
The Summary of Product Characteristics (SPC) for this product is available on the website http://www.anmv.anses.fr/
PUBLIC ASSESSMENT REPORT

<table>
<thead>
<tr>
<th>Legal basis of original application</th>
<th>Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the original decentralised procedure</td>
<td>26/09/2018</td>
</tr>
<tr>
<td>Concerned Member States for original procedure</td>
<td>AT, ES, IT, UK, PT, IE, FI, EL, DE</td>
</tr>
</tbody>
</table>

I. SCIENTIFIC OVERVIEW
The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in both target species; the slight reactions observed are indicated in the SPC. The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition
The product contains 5 mg benazepril hydrochloride and excipients cellulose microcrystalline, lactose monohydrate, povidone, maize starch, silica colloidal anhydrous, magnesium stearate and water purified. There is a coloured coating on the tablet. The packaging of the finished product is a blister made of clear film of PVC/PE/PVDC and aluminium film containing 14 tablets. The particulars of the containers and controls performed are provided and conform to the regulation. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product
The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.
Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is benazepril hydrochloride, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice. The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

A re-test period of 4 years for the active substance is set in the certificate of suitability issued by EDQM.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

Not applicable.
III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

The test product is bioequivalent to the reference product, FORTEKOR 5 marketed by NOVARTIS SANTE ANIMAL.

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

A brief user risk assessment was provided. The product is bioequivalent to the reference product and has the same pharmaceutical form. The qualitative and quantitative composition in active substance is identical for both products. The excipients are not of toxicological concern. Therefore the use and risk of the product can be considered identical to the reference product. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will only be used in non-food animals.

If used as recommended the product will have a negligible impact on the environment.
IV.  CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required.

IV.A Pre-Clinical Studies

Pharmacology

Bioequivalence has been demonstrated between the product and a reference product based on two bioequivalence studies in the dogs and in the cats.

Tolerance in the Target Species of Animals

The applicant has not provided tolerance study which is acceptable because:
- The tested product and the reference product are bioequivalent.
- The excipients of the tested product are deemed unproblematic as regards tolerance.

Furthermore no adverse effects were reported during bioequivalence studies in dogs and cats.

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, efficacy studies are not required. The efficacy claims of the tested product are based on the reference product documentation.

V.  OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.
POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.HEVRA.org).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.